NCT06435312 2026-04-13
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
Clinical Trials
65 trialsNCT06540144 2026-04-13
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT07217587 2026-04-13
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06744920 2026-04-06
RELIEVE
Novartis
Phase 3 Recruiting
NCT06607627 2026-04-01
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06517758 2026-03-30
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06471361 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT05403541 2026-03-25
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Active not recruiting
NCT06799247 2026-03-24
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
Phase 3 Recruiting
NCT06463587 2026-03-19
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT07463521 2026-03-17
MyVision
UCB Pharma
Phase 3 Not yet recruiting
NCT07465289 2026-03-11
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Pharma
Phase 3 Not yet recruiting
NCT04524273 2026-03-10
MINT
Amgen
Phase 3 Active not recruiting
NCT06456580 2026-03-10
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT07039916 2026-03-06
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT04951622 2026-03-03
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04225871 2026-02-27
RAISE-XT
UCB Pharma
Phase 3 Active not recruiting
NCT07215949 2026-02-23
Zilucoplan for Severe gMG Exacerbations
Ohio State University
Phase 3 Recruiting
NCT05644561 2026-02-19
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05070858 2026-02-12
NIMBLE
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT05556096 2026-01-23
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04818671 2026-01-22
ADAPTSC+
argenx
Phase 3 Completed
NCT06342544 2026-01-21
IMCOMG
Fondation Ophtalmologique Adolphe de Rothschild
Phase 3 Recruiting
NCT06764160 2026-01-15
ECU-MG-304
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03971422 2025-12-24
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT06558279 2025-12-15
ADAPT oculus
argenx
Phase 3 Active not recruiting
NCT05681715 2025-11-06
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
UCB Pharma
Phase 3 Completed
NCT04980495 2025-11-05
ADAPT NXT
argenx
Phase 3 Completed
NCT06298552 2025-11-05
ADAPT SERON
argenx
Phase 3 Active not recruiting
NCT05132569 2025-09-09
URSA
Sanofi
Phase 3 Terminated
NCT05514873 2025-09-03
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Pharma
Phase 3 Completed
NCT05868837 2025-08-01
REFINE
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Recruiting
NCT06765161 2025-07-29
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Phase 3 Recruiting
NCT04115293 2025-07-16
RAISE
UCB Pharma
Phase 3 Completed
NCT05737160 2025-05-23
Study of Telitacicept in Generalized Myasthenia Gravis
RemeGen Co., Ltd.
Phase 3 Completed
NCT04650854 2025-04-18
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT04963270 2025-02-28
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Hoffmann-La Roche
Phase 3 Terminated
NCT03759366 2024-12-11
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02950155 2024-10-26
Rinomax
Karolinska Institutet
Phase 3 Completed
NCT06587867 2024-09-19
Seronegative Myasthenia Gravis - Efgartigimod IV
University Health Network, Toronto
Phase 3 Recruiting
NCT03920293 2024-05-28
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03579966 2024-05-07
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Catalyst Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT04124965 2023-09-05
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT05919407 2023-06-26
IMPACT-MG
Leiden University Medical Center
Phase 3 Unknown
NCT05039190 2023-03-08
MG
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Completed
NCT05332210 2023-03-08
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 3 Unknown
NCT04735432 2023-02-28
ADAPTsc
argenx
Phase 3 Completed